EPISODE 108
In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that’s inserted between a patient’s prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology – which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix’s efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.
Podcast Guest
John Pedersen
President & CEO
Augmenix
John Pedersen joined Augmenix in 2014. Previously he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, John was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.
John earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University. He currently serves on the Board of Directors of Therakos and Clinical Innovations, two privately held medical device companies.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.